Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting Interleukin-17 inflammatory Axis in CTEPH

Award Number: R01HL174909
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Targeting Interleukin-17 inflammatory Axis in CTEPH - ABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a deadly sequela following acute pulmonary em- bolism (PE). In CTEPH, the acute PE does not resorb but develops into organized “thrombi,” causing pulmo- nary vascular remodeling, leading to progressive right heart failure and death. The gold standard treatment for CTEPH is surgery, but many patients are not surgical candidates due to comorbidities or surgically inaccessi- ble disease. For these patients, there are only limited options that have only been shown to improve short-term symptoms. Thus, developing novel medical therapies for CTEPH is a significant unmet need. Drug develop- ment has been limited by the significant knowledge gap on how different cell types and signaling pathways within chronic thrombus contribute to pulmonary vascular remodeling and pulmonary hypertension (PH). This puts into context our preliminary studies, using single-cell RNA sequencing (scRNAseq) and ex-vivo culturing of patient thrombus-derived cells, we identified upregulated inflammatory and proliferative signaling pathways that may contribute to chronic thrombus development and pulmonary vascular remodeling. We showed that a phenotypically-modulated smooth muscle cell (SMC) population expresses a high level of PAR1, a receptor that promotes SMC proliferation and migration and propagates IL-17-mediated inflammation. Our data also revealed that SMCs, macrophages, and T cells are enriched for IL-17 signaling, which has been implicated in numerous inflammatory diseases and promotes venous and arterial thrombosis, suggesting a role for the PAR1/IL-17 signaling axis in CTEPH pathogenesis. Thus, our central hypothesis is that the PAR1/IL-17 sig- nal axis propagates abnormal chronic thrombus development and pulmonary vascular remodeling in CTEPH, linking inflammation and pulmonary vascular remodeling in this disease. The overall objective of this applica- tion is to determine the contribution of PAR1/IL-17 signals to the development of abnormal cellular phenotypes in chronic thrombus, initiation, and progression of CTEPH using human samples and animal models. Aim 1 will determine if the PAR1/IL-17 signaling synergistically promotes abnormal thrombus-derived mesenchymal cell phenotypes. In Aim 2, we will evaluate the activity of the PAR1 and IL-17 signaling axes in different immune and mesenchymal cells in human CTEPH using flow cytometry and single-cell technologies. In Aim 3, we will determine whether inhibiting the PAR1/IL-17 signaling axis prevents and reverses CTEPH in vivo using a ro- bust small animal model of CTEPH that we have developed. The rationale for these studies is that defining the mechanisms contributing to inflammation and proliferation will aid the development of novel CTEPH medical therapies. The expected outcome of this project will be to determine whether the PAR1/IL-17 signaling axis promotes disease progression in CTEPH and could serve as a disease target. This will lay the groundwork for future studies on novel CTEPH treatments targeting SMC and immune cell activation. These studies will have a significant positive impact as they will aid in developing new CTEPH therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $672,490 )
2026	2026	THE REGENTS OF THE UNIVERSITY OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Lung Diseases Research	000	2	2/21/2026	NON-COMPETING CONTINUATION	$672,490
														Subtotal = $672,490

Issue Date FY: 2025 ( Subtotal = $723,084 )
2025	2025	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Lung Diseases Research	000	1	4/30/2025	NEW	$723,084
														Subtotal = $723,084

Grand Total All Awards = $1,395,574

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting Interleukin-17 inflammatory Axis in CTEPH

Award Number: R01HL174909

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer